55 results
8-K
PRAX
Praxis Precision Medicines Inc
29 Mar 24
Other Events
4:30pm
, continue its research and development activities in ulixacaltamide, PRAX-562 and PRAX-222 and for working capital and other general corporate purposes
424B5
PRAX
Praxis Precision Medicines Inc
29 Mar 24
Prospectus supplement for primary offering
4:29pm
to accelerate the clinical development of PRAX-628, continue our research and development activities in ulixacaltamide, PRAX-562 and PRAX-222 and for working … research institution collaborators to continue research and development activities relating to our product candidates;
our ability to commercialize our
424B5
PRAX
Praxis Precision Medicines Inc
27 Mar 24
Prospectus supplement for primary offering
4:49pm
the clinical development of PRAX-628, continue our research and development activities in ulixacaltamide, PRAX-562 and PRAX-222 and for working capital … collaborators to continue research and development activities relating to our product candidates;
our ability to commercialize our product candidates
S-3
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Shelf registration
9:08am
of our third-party research institution collaborators to continue research and development activities relating to our product candidates;
our ability … ;
the ability and willingness of our third-party research institution collaborators to continue research and development activities relating to our product
8-K
EX-99.1
j7yx20vr39a uqnbhuy
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
424B5
xiv0nhuhil6l 2ljnpi8
12 Jan 24
Prospectus supplement for primary offering
5:20pm
424B5
2ujd vzdly1
10 Jan 24
Prospectus supplement for primary offering
5:28pm
424B5
avqfdanahkb09viqmcxs
7 Dec 23
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
8b016mg8
7 Nov 23
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
7:35am
8-K
EX-99.1
d2aqdi tylf
9 Aug 23
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8:27am
424B5
x1htjevn9j5iim n3c
20 Jun 23
Prospectus supplement for primary offering
6:02am
424B5
sozc2 rchh5dndlt
15 Jun 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
hsi6x90mo3oodp poax
11 May 23
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
7:31am